drugset
drugset / Trial / NCT01998659

Single Ascending Oral Dose Phase I Study With Px-102

NCT01998659 ↗

Phase 1 Completed 54 enrolled Phenex Pharmaceuticals AG
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of the FXR agonist Px-102 in healthy subjects after single oral dosing.

Timeline

Start
2011-09
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Px-102 Small molecule 0.15 mg/kg Oral
Comparator Px-102 Small molecule 4.5 mg/kg Oral

Indications

No indication recorded.